Hongmei Yong
Overview
Explore the profile of Hongmei Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meng S, Liu H, Xu J, Deng C, Qian X, Chu S, et al.
Research (Wash D C)
. 2025 Jan;
8():0549.
PMID: 39781264
Numerous diseases have been connected to protein arginine methylations mediated by protein arginine methyltransferase 5 (PRMT5). Clinical investigations of the PRMT5-specific inhibitor GSK3326595 are currently being conducted, and the results...
2.
Xu D, Han G, Zhou X, Yong H, Jia Y, Zhao F, et al.
Digestion
. 2024 Apr;
105(4):243-256.
PMID: 38663369
Introduction: This study attempted to investigate how proprotein convertase subtilisin/kexin type 9 (PCSK9) influences the stemness of stomach adenocarcinoma (STAD) cells. Methods: CCK-8 and sphere-formation assays were used to detect...
3.
Shen Z, Dong T, Yong H, Deng C, Chen C, Chen X, et al.
Cell Death Discov
. 2024 Mar;
10(1):151.
PMID: 38519492
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate...
4.
Zhou Y, Yong H, Cui W, Chu S, Li M, Li Z, et al.
Cell Death Discov
. 2023 Aug;
9(1):305.
PMID: 37604866
No abstract available.
5.
Li Z, Chen C, Yong H, Jiang L, Wang P, Meng S, et al.
Cell Death Dis
. 2023 May;
14(5):322.
PMID: 37173306
Protein arginine methyltransferase 2 (PRMT2) is involved in several biological processes via histone methylation and transcriptional regulation. Although PRMT2 has been reported to affect breast cancer and glioblastoma progression, its...
6.
Shen J, Yan J, Du J, Li X, Wei J, Liu Q, et al.
Front Immunol
. 2023 Apr;
14:1133689.
PMID: 37056765
Introduction: Combination therapeutic mode is likely to be the key to enhance the efficacy of immunotherapy in a wider range of cancer patients. Herein, we conducted an open-label, single-arm, multicenter,...
7.
Chen X, Yong H, Chen M, Deng C, Wang P, Chu S, et al.
J Exp Clin Cancer Res
. 2023 Jan;
42(1):34.
PMID: 36694250
Background: Metabolic reprogramming is a hallmark of various cancers. Targeting metabolic processes is a very attractive treatment for cancer. Renal cell carcinoma (RCC) is a type of metabolic disease, and...
8.
Li Z, Wang P, Cui W, Yong H, Wang D, Zhao T, et al.
Cell Biosci
. 2022 Oct;
12(1):176.
PMID: 36273188
Background: DNMT1 has been shown to be highly expressed in a variety of cancers, including breast cancer. However, the mechanism is not very clear. Therefore, we aim to reveal the...
9.
Li Z, Yong H, Wang W, Gao Y, Wang P, Chen X, et al.
J Med Virol
. 2022 Sep;
95(1):e28158.
PMID: 36114164
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 epidemic is worsening. Binding of the Spike1 protein of SARS-CoV-2 with the angiotensin-converting enzyme 2 (ACE2) receptor mediates entry of...
10.
Zhou Y, Yong H, Cui W, Chu S, Li M, Li Z, et al.
Cell Death Discov
. 2022 Apr;
8(1):192.
PMID: 35410446
As the most commonly diagnosed lung cancer, non-small cell lung carcinoma (NSCLC) is regulated by many long noncoding RNAs (lncRNAs). In the present study, we found that SH3PXD2A-AS1 expression in...